Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545719 | 1.00 | SRD5A2 (0.66) | SRD5A2SRD5A1 | |
| SCHEMBL9116882 | 0.89 | SRD5A1 (0.56) | SRD5A2SRD5A1 | |
| SCHEMBL9022346 | 0.88 | SRD5A2 (0.60) | SRD5A2SRD5A1 | |
| SCHEMBL9022210 | 0.88 | SRD5A2 (0.60) | SRD5A2SRD5A1 | |
| SCHEMBL9022217 | 0.88 | SRD5A2 (0.60) | SRD5A2SRD5A1 | |
| SCHEMBL9022357 | 0.88 | SRD5A2 (0.60) | SRD5A2SRD5A1 | |
| SCHEMBL9068013 | 0.87 | SRD5A1 (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL27814934 | 0.87 | SRD5A2 (0.62) | SRD5A2SRD5A1 | |
| SCHEMBL14185033 | 0.85 | SRD5A1 (0.58) | SRD5A2SRD5A1 | |
| SCHEMBL12423999 | 0.85 | SRD5A1 (0.58) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994011387-A2 | A PROCESS FOR THE PRODUCTION OF FINASTERIDE | MERCK & CO., INC. (US) | 1994-05-26 | — | — | WO | claimed |
| EP-1496909-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1116725-B1 | PROCESS FOR OBTAINING 17BETA-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS | RAGACTIVES SL (ES) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003088971-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003027132-A2 | METHOD OF PREPARING 17β-(N-TERT-BUTYLCARBAMOYL)-3-ONE STEROID DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2003-04-03 | — | — | WO | disclosed |
| US-6509466-B2 | Reacting 17 beta-(alkoxycarbonyl)-3-one-4-aza-steroid with lithium tert-butylamide in an organic solvent | RAGA CONSULTORES, S.L. (ES) | 2003-01-21 | — | — | US | disclosed |
| US-20010008895-A1 | Process for obtaining 17 beta-(N-tert-butylcarbamoyl)-3-one4-aza-steroids | RAGA CONSULTORES, S.L. | 2001-07-19 | — | — | US | disclosed |
| EP-1116725-A1 | PROCESS FOR OBTAINING 17BETA-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS | Raga Consultores, S.L. (ES) | 2001-07-18 | — | — | EP | disclosed |
| EP-0542802-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5-g(a)-REDUCTASE INHIBITORS. | UPJOHN CO (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002225-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5α-REDUCTASE INHIBITORS | THE UPJOHN COMPANY (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008895-A1 | Process for obtaining 17 beta-(N-tert-butylcarbamoyl)-3-one4-aza-steroids | CYP17A1, HSD17B7, CYP51A1 | SRD5A2 14/4885SRD5A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.